Background – Urolithiasis, a condition marked by the formation of kidney stones, remains a pressing global health concern due to its high recurrence and limited treatment outcomes. While conventional therapies target symptom management, they often fail to address the underlying mechanisms of stone formation. Withania somnifera (Ashwagandha), a revered medicinal plant in Ayurveda, offers a promising alternative with its broad-spectrum therapeutic effects, including antioxidant, anti-inflammatory, and diuretic properties. This review explores its potential as a holistic solution for managing urolithiasis and associated health conditions.rnMethodsrnA systematic review was conducted to evaluate Withania somnifera's phytochemical composition, pharmacological activities, and anti-urolithiatic potential. Preclinical studies were analyzed for insights into its mechanisms of action, while advanced analytical techniques such as HPLC and GC-MS were reviewed for identifying key bio actives. The role of innovative delivery systems, including Nano formulations, in enhancing efficacy was also assessed.rnResultsrnWithania somnifera exhibits a rich phytochemical profile, including with anolides, flavonoids, and alkaloids, which target critical pathways of kidney stone formation by reducing oxidative stress, inhibiting inflammation, and preventing crystal aggregation. Its nephroprotective effects extend to managing comorbidities like diabetes and hypertension. Emerging Nano formulations further enhance its bioavailability, amplifying its therapeutic potential.rnConclusionrnWithania somnifera represents a paradigm shift in urolithiasis management, offering a natural, multi-mechanistic approach. Future efforts should focus on clinical validation, standardization, and innovative delivery systems to unlock its full therapeutic potential.
EMBAR PUBLISHERSResearch Today, A Better Tomorrow.